AC Immune SA (ACIU)
NASDAQ: ACIU · IEX Real-Time Price · USD
2.350
+0.060 (2.62%)
At close: Apr 26, 2024, 4:00 PM
2.390
+0.040 (1.70%)
After-hours: Apr 26, 2024, 4:06 PM EDT
AC Immune Revenue
In the year 2023, AC Immune had annual revenue of $17.62M with 316.44% growth. Revenue in the quarter ending December 31, 2023 was $17.62M with 1,638,991.91% year-over-year growth.
Revenue (ttm)
$17.62M
Revenue Growth
+316.44%
P/S Ratio
13.23
Revenue / Employee
$132,483
Employees
133
Market Cap
233.11M USD
Revenue Chart
* The company reports in CHF currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17.62M | 13.39M | 316.44% |
Dec 31, 2022 | 4.23M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 17.54M | -96.34M | -84.60% |
Dec 31, 2019 | 113.87M | 106.82M | 1,514.51% |
Dec 31, 2018 | 7.05M | -13.73M | -66.06% |
Dec 31, 2017 | 20.78M | -4.01M | -16.16% |
Dec 31, 2016 | 24.79M | -14.36M | -36.67% |
Dec 31, 2015 | 39.14M | 8.67M | 28.46% |
Dec 31, 2014 | 30.47M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionACIU News
- 6 weeks ago - AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - AC Immune Announces Upcoming Presentations at AD/PD™ 2024 - GlobeNewsWire
- 3 months ago - AC Immune to Regain Global Rights to Crenezumab and Semorinemab - GlobeNewsWire
- 4 months ago - AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases - GlobeNewsWire
- 4 months ago - AC Immune Announces Pricing of Underwritten Offering of Common Shares - GlobeNewsWire
- 4 months ago - AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial - GlobeNewsWire
- 5 months ago - AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO - GlobeNewsWire
- 6 months ago - AC Immune to Present at the Jefferies 2023 London Healthcare Conference - GlobeNewsWire